

66-

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

"BB"

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/12, C07K 14/71S, C12N 15/62, C07K 14/52, 16/28, G01N 33/68, A61K 38/17		A3	(11) International Publication Number: WO 96/22371 (43) International Publication Date: 25 July 1996 (25.07.96)
(21) International Application Number: PCT/US96/00608		PONATH, Paul, D. [US/US]; 45 Upton, No. 3, Boston, MA 02118 (US). POST, Theodore, W. [US/US]; 14 Mandalay Road, Newton, MA 02159 (US). QIN, Shixin [CN/US]; 14 Taft Avenue, Lexington, MA 02173 (US).	
(22) International Filing Date: 19 January 1996 (19.01.96)		(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).	
(30) Priority Data: 08/375,199 19 January 1995 (19.01.95) US		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US Filed on 08/375,199 (CIP) 19 January 1995 (19.01.95)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicants (for all designated States except US): LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). BRIGHAM AND WOMEN'S HOSPITAL [US/US]; 75 Francis Street, Boston, MA 02115 (US). CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US).		(88) Date of publication of the International search report: 17 October 1996 (17.10.96)	
(72) Inventors; and (75) Inventors/Applicants (for US only): GERARD, Craig, J. [US/US]; 117 Walpole Street, Dover, MA 02030 (US). GERARD, Norma, P. [US/US]; 117 Walpole Street, Dover, MA 02030 (US). MACKAY, Charles, R. [AU/US]; 150 Dedham Street, Newton Highlands, MA 02161 (US).			

(54) Title: C-C CHEMOKINE RECEPTOR 3: CKR-3 or. Eos-L2

(57) Abstract

The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C-C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof, to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function. Administration of a compound which inhibits or promotes receptor function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/00608

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/12 C07K14/715 C12N15/62 C07K14/52 C07K16/28
 G01N33/68 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF EXPERIMENTAL MEDICINE, 177 (5). 1993. 1421-1427., XP000579252 GAO J-L ET AL: "STRUCTURE AND FUNCTIONAL EXPRESSION OF THE HUMAN MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA RANTES RECEPTOR" cited in the application see the whole document ---	1,24,26, 27,30, 34,35, 38,40, 43,44
A	J EXP MED, MAR 1 1994, 179 (3) P881-7, UNITED STATES, XP000600041 JOSE PJ ET AL: "Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation." see the whole document ---	1,24,26, 27,30, 34,35, 38,40, 43,44

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

3

Date of the actual completion of the international search

23 August 1996

Date of mailing of the international search report

03.09.96

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Pachdlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Telex 31 651 epo nl.
 Fax (+ 31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 96/00608

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J EXP MED, FEB 1 1994, 179 (2) P751-6, UNITED STATES, XP000600044 DAHINDEN CA ET AL: "Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine." see the whole document ---	1,24,26, 27,30, 34,35, 38,40, 43,44
A	WO,A,92 01810 (LERNER MICHAEL R ;LERNER ETHAN A (US)) 6 February 1992 see abstract; claims 1-17 ---	40,43,44
A	WO,A,94 11504 (GENENTECH INC) 26 May 1994 cited in the application see examples 1,2 ---	1,24,26, 27,30, 34,35, 38,40, 43,44
A	CELL, 72 (3). 1993. 415-425., XP002011150 NEOTE K ET AL: "MOLECULAR CLONING FUNCTIONAL EXPRESSION AND SIGNALING CHARACTERISTICS OF A C-C CHEMOKINE RECEPTOR" see the whole document ---	1,24,26, 27,30,35
A	EP,A,0 475 746 (TAKATSU KIYOSHI) 18 March 1992 see page 6, line 19 - line 24 ---	1,24,26, 27
P,X	JOURNAL OF BIOLOGICAL CHEMISTRY, 270 (28). 1995. 16491-16494., XP002011151 COMBADIERE C ET AL: "Cloning and functional expression of a human eosinophil CC chemokines receptor" see the whole document ---	1-29
T	J BIOL CHEM, MAR 29 1996, 271 (13) P7725-30, UNITED STATES, XP002011152 KITaura M ET AL: "Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3." ---	1-29
T	J EXP MED, MAY 1 1996, 183 (5) P2349-54. UNITED STATES, XP000600043 DAUGHERTY BL ET AL: "Cloning, expression, and characterization of the human eosinophil eotaxin receptor." see the whole document ---	1-29
3 1	E WO,A,96 22371 (LEUKOSITE INC ;BRIGHAM & WOMENS HOSPITAL (US); CHILDRENS MEDICAL C) 25 July 1996 see the whole document -----	1-46

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/00608

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Please see Further Information sheet enclosed.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US96/00608

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Remark: Although claim 48, and claim 47 partially as far as it concerns an *in vivo* method, are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/00608

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9201810	06-02-92	US-A- 5462856 EP-A- 0539518 JP-T- 6502757	31-10-95 05-05-93 31-03-94
-----	-----	-----	-----
WO-A-9411504	26-05-94	EP-A- 0669979 JP-T- 8503463	06-09-95 16-04-96
-----	-----	-----	-----
EP-A-0475746	18-03-92	JP-A- 6054690 US-A- 5453491	01-03-94 26-09-95
-----	-----	-----	-----
WO-A-9622371	25-07-96	NONE	-----
-----	-----	-----	-----